Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
about
Cyclic nucleotide specific phosphodiesterases of Leishmania major.Interventions for American cutaneous and mucocutaneous leishmaniasisAntileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum partheniumGlibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasisVisceral leishmaniasis caused by Leishmania infantum in a Spanish patient in Argentina: What is the origin of the infection? Case reportTheranostic applications of phage display to control leishmaniasis: selection of biomarkers for serodiagnostics, vaccination, and immunotherapyDrug repurposing and human parasitic protozoan diseasesAntigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral LeishmaniasisEthnomedicines and anti-parasitic activities of Pakistani medicinal plants against Plasmodia and Leishmania parasitesAdvances in Development of New Treatment for LeishmaniasisEfficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trialDevelopments in the treatment of visceral leishmaniasisIdentification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screenReactive oxygen species production and mitochondrial dysfunction contribute to quercetin induced death in Leishmania amazonensisTherapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c miceHigh throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinaseOver-expression of 60s ribosomal L23a is associated with cellular proliferation in SAG resistant clinical isolates of Leishmania donovaniIn vitro susceptibilities of wild and drug resistant leishmania donovani amastigote stages to andrographolide nanoparticle: role of vitamin E derivative TPGS for nanoparticle efficacyDeficiency of p110δ isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovaniAntileishmanial activity of semisynthetic lupane triterpenoids betulin and betulinic acid derivatives: synergistic effects with miltefosineTerpenes increase the lipid dynamics in the Leishmania plasma membrane at concentrations similar to their IC50 valuesSpecies-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1Chemotherapeutic potential of 17-AAG against cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensisImmunotherapeutic Potential of Eugenol Emulsion in Experimental Visceral LeishmaniasisCharacterization of a Novel Endoplasmic Reticulum Protein Involved in Tubercidin Resistance in Leishmania majorDrug resistance in leishmaniasisScaffold proteins LACK and TRACK as potential drug targets in kinetoplastid parasites: Development of inhibitorsMetabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical diseaseAntileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major AmastigotesDevelopmentally regulated sphingolipid degradation in Leishmania majorInfectivity of Leishmania mexicana is associated with differential expression of protein kinase C-like triggered during a cell-cell contactDiscrepant prevalence and incidence of Leishmania infection between two neighboring villages in Central Mali based on Leishmanin skin test surveys.In vitro activity of the hydroethanolic extract and biflavonoids isolated from Selaginella sellowii on Leishmania (Leishmania) amazonensis.Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.Antileishmanial activity of the terpene nerolidol.Potential Challenges of Controlling Leishmaniasis in Sri Lanka at a Disease Outbreak.Cell death in amastigote forms of Leishmania amazonensis induced by parthenolideBeta-carboline-3-carboxamide derivatives as promising antileishmanial agents.Biochemical and genetic analysis of methylenetetrahydrofolate reductase in Leishmania metabolism and virulence.Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
P2860
Q21093362-252FC965-9A6C-4872-AE68-4C3F090005DEQ24241646-8498254C-0262-4B88-A454-6C30C4CD7825Q24558685-370A6E1A-86E5-470A-A640-1C78460D2D33Q24674183-2C2BA44A-4651-4AD8-90AC-05D887B3EB03Q24804210-5D99364A-A9DF-46A2-9251-5F3457996567Q26796580-FA8589FB-0892-417B-A05F-94B41F538DACQ26999453-8ACBE780-C1AD-4FC7-900A-6AA2C232940AQ27318412-1EC814ED-9DA7-4077-B15F-30ED5BCBE0C3Q27468677-AAA2CB8D-3DD1-4CDB-A26B-FE1066067EDDQ28082097-6EA716C0-CB01-4718-9A51-39AAD2FCE1A3Q28241775-1A503ED6-222B-4E7D-8AC8-09BBF3D6A313Q28256441-A6E77213-C8BC-43F6-8493-18133B575F5BQ28471705-979E8FC3-7292-4573-AB96-8605B5643C53Q28477090-F0E4854E-47A6-4E53-A908-FD9E7BDCC732Q28477398-96AA140D-888D-4470-9472-F34504312E0CQ28477651-6DF5CDC2-5612-4E1B-83F2-898C3FB49EE3Q28536134-33969F2E-0F56-4144-B531-A8DCE9A32A5DQ28536688-2B6E8FDC-8F82-4772-AA91-20A82AE34865Q28539842-DFE89B5F-C897-44C7-A4F7-22E42899398DQ28541041-9F00D40B-4381-4F3F-9A55-9709ED0918C7Q28541719-C9694302-6C2F-443E-A35C-FD2612B911CDQ28543678-6E8D6352-5D23-4759-A6B5-10D803F4F42FQ28544030-1369322E-D75F-4831-8375-AA200CCC3068Q28552919-A731B9BD-6813-422C-A6B8-9CD7DBC8E168Q28553952-5F0D77ED-DBC8-4560-81C3-CF128C82D6DEQ29616242-EE79C346-D79A-4CE8-B2D5-17C52B1D0526Q30359734-9E5C390E-AF77-4A9C-8B88-502397D602A9Q30426102-D06E1D8D-BBCA-44FD-9246-F714FD421F74Q30488470-71540E0C-5180-4B62-93FD-D5E724017BD0Q31047779-6EC0FFA7-4202-4B5D-A55F-F5A8E5230E97Q33511990-A5ED8616-1373-4CF4-9CD9-5924ACD9EEEBQ33519080-E2761102-9CD0-47C1-8500-E6EE1702408DQ33587086-08ED2ED5-547A-4FEF-9071-75504DD02EB1Q33749424-707B5D4B-B2C8-4D9C-9C97-3C73FC87EFD8Q33770134-BC8FFDA8-E3E5-4CC1-9EFE-76977F5A1D78Q33786761-85E52726-B1FB-40D5-A082-B75A46935562Q33795080-78347DCC-29E2-4F0B-8089-C285872DCD9DQ33873641-16C336B9-7A27-487A-A6B3-16EA03217F9AQ34000109-06E62DCD-EB21-4EEA-988C-31D4283D7CF9Q34033949-9F43F29D-C5D0-445F-B35B-D8C5CD6A5597
P2860
Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
@ast
Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
@en
type
label
Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
@ast
Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
@en
prefLabel
Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
@ast
Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
@en
P356
P1476
Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
@en
P2093
Graham H Coombs
Simon L Croft
P304
P356
10.1016/J.PT.2003.09.008
P577
2003-11-01T00:00:00Z